Cost-Effectiveness Analysis of Rivaroxaban in Secondary Prevention of ACS in Sweden

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.08.1272
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pcv76 - Cost-Effectiveness Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness Analysis of Bisphosphonates for Secondary Prevention of Hip Fracture in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

845 Cost-Effectiveness Analysis in Fire Prevention

Injury Prevention
EnvironmentalPublic HealthOccupational Health
2016English

Pcv40 - Budget Impact Analysis of Rivaroxaban in the Secondary Prevention of Acute Coronary Syndromes in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Cost of Illness Attributable to Diabetic Foot and Cost-Effectiveness of Secondary Prevention in Peru

BMC Health Services Research
Health Policy
2015English

Cost-Effectiveness of Rivaroxaban for the Treatment of Pulmonary Embolism in Canada

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation – A Multinational Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Pcv79 - Real-World Cost-Effectiveness of Rivaroxaban Compared With Vitamin K Antagonists in the Context of Stroke Prevention in Atrial Fibrillation in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Intact Cost-Effectiveness of Screening for Abdominal Aortic Aneurysms in Sweden

European Journal of Vascular and Endovascular Surgery
SurgeryCardiovascular MedicineCardiology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy